Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.

MARKN.

Xbrane announces today that it has appointed Jane Benyamin as acting CFO as of January 9, 2025. As previously announced, the company's current CFO, Anette Lindqvist, is stepping down from the role of CFO with the intention of reducing her operational work to retire.

Jane has experience from several senior finance roles within Life Science from Bluefish Pharmaceuticals, Pensa Pharma and Medivir among others.

"I welcome Jane to Xbrane and I am convinced that her experience from the industry will be very valuable in the future," says Martin Åmark, CEO of Xbrane. "At the same time, I want to thank Anette Lindqvist for her valuable efforts as CFO and wish her all the best in the future"

Jane Benyamin will be acting CFO until further notice starting today, January 9, 2025. Anette Lindqvist will be available for a period to ensure a smooth transition.

Datum 2025-01-09, kl 14:00
Källa MFN
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.